Initiate Phase 2 clinical trial of ADX-2191 in retinitis pigmentosa

Delivered after the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 28 Oct 2021
Due: 31 Dec 2021
Delivered: by 17 Mar 2022

Deadline
Met
Late
Not met
Today

What the company said

“Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa On Track to Initiate in the Fourth Quarter of 2021”

SourceAldeyra Therapeutics, Inc. Form 8-K press release, 2021-10-28
FilingSEC filing index
Deadline as statedin the Fourth Quarter of 2021
Deadline used31 Dec 2021, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-ALDX-003447
Cite as https://keptindex.org/c/KI-C-2021-ALDX-003447/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced in March 2022 that the Phase 2 clinical trial for ADX-2191 in retinitis pigmentosa was initiated in the first quarter of 2022, missing the Q4 2021 deadline.

A
Aldeyra Therapeutics, Inc. 8-K filed 2022-03-17 Regulatory filing · published 17 Mar 2022 · retrieved 2 Oct 2026 · kept permanently by the SEC
“Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa Initiated in the First Quarter of 2022” ✓ confirmed on the page

Market reaction: the shares moved +12.3% against the S&P 500 over the three sessions around the disclosure (16 Mar 2022 to 21 Mar 2022). What this measures

Checked 2 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +1461 days
Language weakened: firm → expected
5 versions

Version 1 · original · stated 28 Oct 2021

Deadline 31 Dec 2021 (“in the Fourth Quarter of 2021”) · wording firm
Version 2 · stated 17 Mar 2022

Deadline 31 Dec 2022 (“in the second half of 2022”) · wording expected

“Results from... the Phase 2 clinical trial of ADX-2191 in retinitis pigmentosa, are expected in the second half of 2022.”
Source for this version
Version 3 · stated 14 Sep 2022

Deadline 30 Jun 2023 (“the first half of 2023”) · wording expected

“Results from the Phase 2 clinical trial of ADX-2191 in retinitis pigmentosa are expected in the first half of 2023.”
Source for this version
Version 4 · stated 3 Apr 2025

Deadline 30 Jun 2025 (“H1 2025”) · wording expected

“Phase 2/3 clinical trial initiation expected in H1 2025”
Source for this version
Version 5 · stated 6 May 2025

Deadline 31 Dec 2025 (“in 2025”) · wording expected

“Phase 2/3 clinical trial initiation expected in 2025”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Phase 2 clinical trial of ADX-2191
Language: Firm (“will”, “on track to”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.